Lantheus Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantheus Holdings, Inc. on January 25, 2017. The report discloses a corporate governance change involving the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine directors.
- New Appointment: Julie H. McHugh was appointed as a Class II Director, effective January 25, 2017. Her initial term expires at the 2017 annual meeting of stockholders.
- Committee Assignment: Ms. McHugh was appointed as a member of the Compensation Committee.
Management Commentary and Compensation
Ms. McHugh brings over 30 years of experience in pharmaceutical, biotech, and medical device industries, including prior roles as COO of Endo Health Solutions, Inc. and CEO of Nora Therapeutics, Inc.
Compensation Arrangements:
- Cash Fees: $50,000 per calendar year for Board service (prorated for 2017) and an additional $7,500 annual fee for Compensation Committee service (prorated for 2017).
- Equity Grant: An initial grant of 2,671 shares of restricted common stock, vesting in full on January 25, 2018.
- Other: Reimbursement for out-of-pocket expenses and standard indemnification rights.
Investor Verification Checklist
- Verify the effective date of the Board size increase and Ms. McHugh's term expiration.
- Confirm the vesting schedule and number of shares for the restricted stock grant.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for any changes to the Compensation Committee composition.